Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19-Reference-Cited by-同舟云学术

Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19

Published:2023-01-09 Issue: Volume:9 Page:
ISSN:2296-858X
Container-title:Frontiers in Medicine
language:
Short-container-title:Front. Med.

Author:

Baldi Federico,Dentone Chiara,Mikulska Malgorzata,Fenoglio Daniela,Mirabella Michele,Magnè Federica,Portunato Federica,Altosole Tiziana,Sepulcri Chiara,Giacobbe Daniele Roberto,Uras Chiara,Scavone Graziana,Taramasso Lucia,Orsi Andrea,Cittadini Giuseppe,Filaci Gilberto,Bassetti Matteo

Abstract

COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with the host immune system and the role of therapy still remains only partly understood. There are no data regarding the use of monoclonal antibodies and the combination of two antivirals in fighting viral replication and disease progression. We report the cases of two patients, both treated with rituximab for non-Hodgkin lymphoma and granulomatosis with polyangiitis, respectively, and both hospitalized for COVID-19 with positive SARS-CoV-2 RNAemia, who were successfully treated with a salvage combination therapy with sotrovimab, remdesivir and nirmatrelvir/ritonavir.

Publisher

Frontiers Media SA

Subject

General Medicine

Reference46 articles.

1. Remdesivir for the treatment of COVID-19 — final report.;Beigel;N Engl J Med.,2020

2. REGEN-COV antibody combination and outcomes in outpatients with COVID-19.;Weinreich;N Engl J Med.,2021

3. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.;Lancet.,2022

4. Bamlanivimab plus etesevimab in mild or moderate COVID-19.;Dougan;N Engl J Med.,2021

5. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab.;Gupta;N Engl J Med.,2021

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma;Journal of Infection and Chemotherapy;2024-08

2. Lessons learnt from broad-spectrum coronavirus antiviral drug discovery;Expert Opinion on Drug Discovery;2024-07-30

3. A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments;AM J CASE REP;2024

4. Antiviral combination regimens as rescue therapy in immunocompromised hosts with persistent COVID-19;Journal of Chemotherapy;2024-06-14

5. Major Metabolites fromHypericum PerforatumL., Hyperforin and Hypericin, are both active against Human Coronaviruses;2024-04-13